The cowpea mosaic virus (CPMV), a harmless plant virus that infects black-eyed peas, is emerging as a novel cancer immunotherapy. Rather than killing tumor cells directly, CPMV activates the immune system, turning the tumor microenvironment from immunosuppressive into highly inflammatory and responsive to attack.
When injected into tumors, CPMV acts as a strong “danger signal,” stimulating interferon production and activating Toll-like receptor 7. This recruits immune cells such as neutrophils, macrophages, and natural killer cells to the tumor site. At the same time, the immune system learns to recognize cancer cells, activating B and T cells to create long-lasting anti-tumor memory and potentially triggering systemic effects like the abscopal response.
CPMV offers several advantages: it is safe in humans, inexpensive to produce, and effective across multiple cancer types in preclinical studies. Now moving toward clinical trials, it represents a promising, nature-inspired strategy that could enhance existing therapies like chemotherapy and checkpoint inhibitors.